Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

As Orphan Drugs Gain More Attention, FDA Releases Development Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Straightforward draft document seems aimed at entities that have limited experience working with the agency.


Related Content

PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
In Manufacturing, Absence Of Evidence Is Not Evidence Of Absence, FDA Tells BioMarin
Biomarkers In Orphan Studies Still Need Past Experience, FDA Says
Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies
Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says


Related Companies